Copeptin (C-terminal pro Arginine-Vasopressin) is an independent long-term prognostic marker in heart failure with reduced ejection fraction

Heart Lung and Circulation

Volumn 24, Issue 4, 2015, Pages 359-367

  Pozsonyi, Zoltán ^a   Förhécz, Zsolt ^a   Gombos, Tímea ^a   Karádi, István ^a   Jánoskuti, Lívia ^a   Prohászka, Zoltán ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

B type natriuretic peptide; Copeptin; Heart failure; Mortality; Vasopressin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; COPEPTIN; BIOLOGICAL MARKER; GLYCOPEPTIDE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CELLULAR DISTRIBUTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POST HOC ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; UREA NITROGEN BLOOD LEVEL; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

AGED; BIOMARKERS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLYCOPEPTIDES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SURVIVAL RATE;

EID: 84925078578     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2014.10.008     Document Type: Article

References (28)

1. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Bohm M., Dickstein K., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012, 33(14):1787-1847.
2. Goldsmith S.R. Vasopressin as vasopressor. Am J Med. 1987, 82(6):1213-1219.
3. Acher R., Chauvet J., Rouille Y. Dynamic processing of neuropeptides: sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport. J Mol Neurosci. 2002, 18(3):223-228.
4. Stoiser B., Mortl D., Hulsmann M., Berger R., Struck J., Morgenthaler N.G., et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006, 36(11):771-778.
5. Tentzeris I., Jarai R., Farhan S., Perkmann T., Schwarz M.A., Jakl G., et al. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail. 2011, 13(7):726-733.
6. Neuhold S., Huelsmann M., Strunk G., Stoiser B., Struck J., Morgenthaler N.G., et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008, 52(4):266-272.
7. Maisel A., Xue Y., Shah K., Mueller C., Nowak R., Peacock W.F., et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail. 2011, 4(5):613-620.
8. Nickel C.H., Bingisser R., Morgenthaler N.G. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med. 2012, 10:7.
9. Katan M., Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly. 2010, 140:w13101.
10. Ferguson J.W., Therapondos G., Newby D.E., Hayes P.C. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci (Lond). 2003, 105(1):1-8.
11. Forhecz Z., Gombos T., Borgulya G., Pozsonyi Z., Prohaszka Z., Janoskuti L. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J. 2009, 158(4):659-666.
12. Czucz J., Cervenak L., Forhecz Z., Gombos T., Pozsonyi Z., Kunde J., et al. Serum soluble E-selectin and NT-proBNP levels additively predict mortality in diabetic patients with chronic heart failure. Clin Res Cardiol. 2012, 100(7):587-594.
13. Gombos T, Forhecz Z, Pozsonyi Z, Szeplaki G, Kunde J, Fust G, et al. Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure. Clin Res Cardiol. 101(8):607-15.
14. Gombos T., Forhecz Z., Pozsonyi Z., Wallentin S., Papassotiriou J., Kunde J., et al. Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure. Inflamm Res. 2009, 58(6):298-305.
15. Gombos T., Mako V., Cervenak L., Papassotiriou J., Kunde J., Harsfalvi J., et al. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost. 2009, 102(3):573-580.
16. Gombos T., Forhecz Z., Pozsonyi Z., Janoskuti L., Prohaszka Z. Interaction of serum 70-kDa heat shock protein levels and HspA1B (+1267) gene polymorphism with disease severity in patients with chronic heart failure. Cell Stress Chaperones. 2008, 13(2):199-206.
17. Cook N.R. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem. 2008, 54(1):17-23.
18. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008, 27(2):157-172. discussion 207-12.
19. Balling L., Kistorp C., Schou M., Egstrup M., Gustafsson I., Goetze J.P., et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Card Fail. 2012, 18(5):351-358.
20. Masson S., Latini R., Carbonieri E., Moretti L., Rossi M.G., Ciricugno S., et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail. 2006, 12(4):338-347.
21. Alehagen U., Dahlstrom U., Rehfeld J.F., Goetze J.P. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA. 2011, 305(20):2088-2095.
22. Palazzuoli A., Gallotta M., Quatrini I., Nuti R. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag. 2010, 6:411-418.
23. Schrier R.W. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med. 2006, 119(7 Suppl 1):S47-S53.
24. Katan M., Morgenthaler N., Widmer I., Puder J.J., Konig C., Muller B., et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett. 2008, 29(3):341-346.
25. Potocki M., Reichlin T., Thalmann S., Zellweger C., Twerenbold R., Reiter M., et al. Diagnostic and prognostic impact of copeptin and high-sensitivity cardiac troponin T in patients with pre-existing coronary artery disease and suspected acute myocardial infarction. Heart. 2012, 98(7):558-565.
26. Gheorghiade M., Konstam M.A., Burnett J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007, 297(12):1332-1343.
27. Konstam M.A., Gheorghiade M., Burnett J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007, 297(12):1319-1331.
28. Lanfear D.E., Sabbah H.N., Goldsmith S.R., Greene S.J., Ambrosy A.P., Fought A.J., et al. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2013, 6(1):47-52.